Michelle C. Schaeffer

Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases

Philip A. Harris, Scott B. Berger, Jae Uk Jeong et al. · Journal of Medicinal Chemistry · 2017 · 475 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Cutting Edge: RIP1 Kinase Activity Is Dispensable for Normal Development but Is a Key Regulator of Inflammation in SHARPIN-Deficient Mice

Scott B. Berger, Viera Kasparcova, Sandy Hoffman et al. · The Journal of Immunology · 2014 · 373 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

DNA-Encoded Library Screening Identifies Benzo[<i>b</i>][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors

Philip A. Harris, Bryan W. King, Deepak Bandyopadhyay et al. · Journal of Medicinal Chemistry · 2016 · 275 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +12

Characterization of GSK′963: a structurally distinct, potent and selective inhibitor of RIP1 kinase

SB Berger, Philip A. Harris, Rakesh Nagilla et al. · Cell Death Discovery · 2015 · 150 citations · Full text

Life Sciences, Medicinal Chemistry, Pharmacology +16

Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis

Philip A. Harris, Deepak Bandyopadhyay, Scott B. Berger et al. · ACS Medicinal Chemistry Letters · 2013 · 137 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15